These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

879 related articles for article (PubMed ID: 21460794)

  • 1. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.
    Chowdhury R; Yeoh KK; Tian YM; Hillringhaus L; Bagg EA; Rose NR; Leung IK; Li XS; Woon EC; Yang M; McDonough MA; King ON; Clifton IJ; Klose RJ; Claridge TD; Ratcliffe PJ; Schofield CJ; Kawamura A
    EMBO Rep; 2011 May; 12(5):463-9. PubMed ID: 21460794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
    Xu W; Yang H; Liu Y; Yang Y; Wang P; Kim SH; Ito S; Yang C; Wang P; Xiao MT; Liu LX; Jiang WQ; Liu J; Zhang JY; Wang B; Frye S; Zhang Y; Xu YH; Lei QY; Guan KL; Zhao SM; Xiong Y
    Cancer Cell; 2011 Jan; 19(1):17-30. PubMed ID: 21251613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.
    Losman JA; Kaelin WG
    Genes Dev; 2013 Apr; 27(8):836-52. PubMed ID: 23630074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.
    Gunn K; Myllykoski M; Cao JZ; Ahmed M; Huang B; Rouaisnel B; Diplas BH; Levitt MM; Looper R; Doench JG; Ligon KL; Kornblum HI; McBrayer SK; Yan H; Duy C; Godley LA; Koivunen P; Losman JA
    Cancer Discov; 2023 Jun; 13(6):1478-1497. PubMed ID: 36847506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.
    Losman JA; Looper RE; Koivunen P; Lee S; Schneider RK; McMahon C; Cowley GS; Root DE; Ebert BL; Kaelin WG
    Science; 2013 Mar; 339(6127):1621-5. PubMed ID: 23393090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on the Interaction of the Histone Demethylase KDM5B with Tricarboxylic Acid Cycle Intermediates.
    Tarhonskaya H; Nowak RP; Johansson C; Szykowska A; Tumber A; Hancock RL; Lang P; Flashman E; Oppermann U; Schofield CJ; Kawamura A
    J Mol Biol; 2017 Sep; 429(19):2895-2906. PubMed ID: 28827149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
    Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
    Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
    Chang S; Yim S; Park H
    Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [(R)-2-hydroxyglutarate or (R)-2HG is an oncometabolite].
    Larsen CJ
    Bull Cancer; 2013; 100(7-8):655. PubMed ID: 24063024
    [No Abstract]   [Full Text] [Related]  

  • 10. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
    Koivunen P; Lee S; Duncan CG; Lopez G; Lu G; Ramkissoon S; Losman JA; Joensuu P; Bergmann U; Gross S; Travins J; Weiss S; Looper R; Ligon KL; Verhaak RG; Yan H; Kaelin WG
    Nature; 2012 Feb; 483(7390):484-8. PubMed ID: 22343896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia Induces Production of L-2-Hydroxyglutarate.
    Intlekofer AM; Dematteo RG; Venneti S; Finley LW; Lu C; Judkins AR; Rustenburg AS; Grinaway PB; Chodera JD; Cross JR; Thompson CB
    Cell Metab; 2015 Aug; 22(2):304-11. PubMed ID: 26212717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability.
    Gunn K; Losman JA
    Cold Spring Harb Perspect Med; 2024 May; 14(5):. PubMed ID: 38191174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncometabolite D-2-Hydroxyglutarate enhances gene silencing through inhibition of specific H3K36 histone demethylases.
    Janke R; Iavarone AT; Rine J
    Elife; 2017 Mar; 6():. PubMed ID: 28346139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Hydroxyglutarate in Cancer Cells.
    Ježek P
    Antioxid Redox Signal; 2020 Nov; 33(13):903-926. PubMed ID: 31847543
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms.
    Schaefer IM; Hornick JL; Bovée JVMG
    Lab Invest; 2018 Apr; 98(4):414-426. PubMed ID: 29339836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of the oncometabolite enantiomers of 2-hydroxyglutarate and their metabolism by diverse dehydrogenases.
    Garcia I; Cornely K; Peterson CN; Berkmen MB
    Essays Biochem; 2024 Oct; 68(2):161-171. PubMed ID: 38919140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway.
    Carbonneau M; M Gagné L; Lalonde ME; Germain MA; Motorina A; Guiot MC; Secco B; Vincent EE; Tumber A; Hulea L; Bergeman J; Oppermann U; Jones RG; Laplante M; Topisirovic I; Petrecca K; Huot MÉ; Mallette FA
    Nat Commun; 2016 Sep; 7():12700. PubMed ID: 27624942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
    Yang H; Ye D; Guan KL; Xiong Y
    Clin Cancer Res; 2012 Oct; 18(20):5562-71. PubMed ID: 23071358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.
    Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P
    Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.